Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cencora, Inc. Common Stock (NY:COR)

314.12 +3.51 (+1.13%)
Official Closing Price Updated: 4:10 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cencora, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
What To Expect From Clover Health’s (CLOV) Q4 Earnings
Health insurance company Clover Health (NASDAQ:CLOV) will be reporting results tomorrow afternoon. Here’s what to look for. 
Via StockStory
1 Healthcare Stock to Hold Forever and 2 to Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
The Ultimate Guide To Stock Investing Success
A discussion about how you can really identify stocks that you can add to your portfolio that will be winners in the long run. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Earnings Scheduled For February 5, 2025
 
Via Benzinga
$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Breaking Down Cencora: 6 Analysts Share Their Views
 
Via Benzinga
Humana Earnings On Deck: Investors Brace For Slower Growth Clip
Humana to release Q4 2024 earnings on Feb. 11 before market hours. Previous quarter saw 15.2% revenue increase, EPS beat but missed guidance. 
Via Benzinga
Humana (HUM) Q4 Earnings: What To Expect
Health insurance company Humana (NYSE:HUM) will be reporting results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Friday. Stay informed about the market activity below. 
Via Chartmill
Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move
Walgreens Boots Alliance further reduced stake in Cencora. Walgreens reports early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an... 
Via Benzinga
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Looking Into Cencora's Recent Short Interest
 
Via Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
(COR) - Analyzing Cencora's Short Interest
 
Via Benzinga
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Looking Into Cencora's Recent Short Interest
 
Via Benzinga
McKesson Stock Gets A RS Rating Lift To 75
The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75. 
Via Investor's Business Daily
Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines
Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised. 
Via Benzinga
Cencora (NYSE:COR) Reports Upbeat Q4
Healthcare distributor Cencora (NYSE:COR) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 12.8% year on year to $81.49 billion. Its non-GAAP profit of $3.73 per... 
Via StockStory
Cencora Reports Fiscal 2025 First Quarter Results
From Cencora
Via Business Wire
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60. 
Via Benzinga
Cardinal Health Stock Sees IBD RS Rating Improve To 71
In a welcome move, Cardinal Health stock saw its Relative Strength (RS) Rating rise from 65 to 71 on Friday. 
Via Investor's Business Daily
Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release
From Cencora
Via Business Wire
Cencora Completes Acquisition of Retina Consultants of America
From Cencora
Via Business Wire
Cencora Closes $1.8 Billion Senior Notes Offering
From Cencora
Via Business Wire
Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035
From Cencora
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.